Cerenome (CNSY) vs Niki BioSolutions (NIKI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Niki BioSolutions (NIKI) has outperformed Cerenome (CNSY) over the past year, losing 75.9% versus a loss of 89.0%. Over five years, NIKI leads with a -98.5% price change compared with -99.7% for CNSY. Cerenome is the larger company by market cap ($14.6 million vs $12.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSY | NIKI |
|---|---|---|
| Share price | $1.93 | $4.00 |
| Market cap | $14.65M | $12.47M |
| 1-day change | +7.82% | -7.41% |
| YTD return | -84.86% | -62.26% |
| 1-year return | -88.97% | -75.90% |
| 5-year return | -99.71% | -98.46% |
| EPS (TTM) | $-3.36 | $-2.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.00 | $17.60 |
| 52-week low | $1.49 | $4.00 |
| Distance from 52-week high | -89.84% | -77.27% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1337.82% | — |
| Average volume | 122.41K | 157.63K |
| Shares outstanding | 7.59M | 2.94M |
| Employees | 28 | 1 |
| Sector | Health Care | Industrials |
| Industry | Medical/Dental Instruments | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NIKI has outperformed CNSY by 13.1 percentage points over the past year.
- The two companies sit in different sectors: Cerenome in Health Care and Niki BioSolutions in Industrials.
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
CNSY vs NIKI FAQ
Which is bigger, Cerenome or Niki BioSolutions?
Cerenome (CNSY) is larger, with a market capitalization of $14.65M compared with $12.47M for Niki BioSolutions (NIKI).
Which stock has performed better over the past year, CNSY or NIKI?
NIKI returned -75.90% over the past 12 months, compared with -88.97% for CNSY (price return, excluding dividends). Past performance does not predict future results.
Are Cerenome and Niki BioSolutions in the same industry?
No. Cerenome is in the Health Care sector, while Niki BioSolutions is in Industrials.